Human tissue kallikreins are a family of serine peptidases present in almost every tissue of the human body (1) . Among the members of the kallikrein family, Kallikrein 5 (KLK5) and Kallikrein 7 (KLK7) appear to be most abundantly expressed in human skin, where a possible role in the desquamation process has been reported (2) . Also, there is now growing evidence that over-expression of these enzymes occurs in endocrine-related malignancies including ovarian, breast and testicular cancer (3) . In addition, recently we have described the ability of KLK5 to hydrolyze plasminogen releasing active plasmin (4) , which can represent a new way to understand its involvement in cancer and inflammation processes, in which KLK5 appear to be up regulated.
Despite the evidences of the importance of KLK5 and KLK7 for some pathological processes, so far there are few inhibitors described for both enzymes (5-7). Recently we have identified some natural and synthetic compounds that inhibited KLK5 and KLK7 in the low micromolar range (8) (9) . In our efforts to find new inhibitors for KLKs, herein we report a new series of potent KLK5 and KLK7 isomannidebased peptidomimetic inhibitors using enzyme inhibition kinetic studies and molecular modeling.
The synthesis of the isomannide-based peptidomimetic derivatives were previously described by Barros et al. (10) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 rigidity of this scaffold allows the compound to be fixed in its bioactive conformation. In our previous work (9), we identified two compounds that inhibited KLK5/KLK7 with K i values in the micromolar range. In order to improve the inhibitory activity against KLK5 and KLK7, we designed a new series of peptidomimetics by the introduction of Nprotected amino acid side chains into the isomannidebased scaffold. These new compounds are characterized by the presence of an N-protected amino acid coupled to the isomannide scaffold through an amide or ester bond (Figure 1) . None of the compounds were able to inhibit the activity of KLK1 and KLK6 in an initial screen. On the other hand, seven compounds in these series showed significant to moderate activity against KLK5/KLK7 with IC 50 ranging from 3.7 to 19.6 µM ( Table 1) . A pairwise analysis between the isomannide-based ester 2-8 and amide 10-16 derivatives shows that in general the former were better KLK5 inhibitors than the later ones. The isomannide-based ester derivatives with the Boc-protecting group and containing a hydrophobic amino acid side chain (Compounds 1, 2, 4 and 5) were poor KLK5 inhibitors, but their potencies against KLK7 were between 6 and 21-fold higher. The only exception was compound 2, which is the weakest inhibitor of both enzymes. On the other hand, the compounds bearing a protected charged or polar amino acid side chain (Compounds 3, 8 and 9) exhibited potency parameters comparable against both enzymes. A progressive enhancement in the potency was observed in the case of compounds 6 and 7 with IC 50 against KLK5 of 3.9 µM and 3.7 µM, respectively. They also inhibit KLK7, but with an IC 50 between 4-5 times higher. Compound 6 has a phenylalanine residue between the isomannide ring and a Cbzprotected proline, while in compound 7 the proline is directly attached do isomannide ring. The comparison of these two compounds shows that phenylalanine residue can be eliminated without compromising the potency. Also, it appears that the stereochemistry configuration of the pyrrolidine ring in proline has a drastic effect on the potency of the compounds against KLK5. In compound 1 an Sconfiguration in the pyrrolidine ring shows an IC 50 of 521 ± 7 µM and was 140-fold less potent than the corresponding R-enantiomer (compound 7; KLK5 IC 50 = 3.7 ± 0.1 µM). In contrast, KLK7 seems to be less restrictive since the potency against this enzyme for these two compounds are nearly identical.
For the isomannide-based amide derivatives the SAR indicates that the Boc-protected compounds with hydrophobic amino acid side chains (Compounds 10, 12 and 13) are more potent against KLK5 than KLK7, which is in opposite to the observed inhibition pattern for the ester derivatives. Moreover, compounds with a protected charged or polar amino acid side chain (Compounds 11, 16 and 19) inhibit both enzymes with almost the same potencies. Compounds with a Cbz-protecting group (Compounds 14 and 15) inhibit the enzymes in different levels. While compound 14 is a weak inhibitor for both KLK5 and KLK7 enzymes, compound 15 is a poor inhibitor of KLK5 but inhibits KLK7 with an IC 50 of 23.6 µM. Compound 17 with a protected histidine side chain inhibits KLK7 with an IC 50 six times lower than KLK5. Finally, compound 18 with a phenylalanine residue between the isomannide ring and a Cbz-protected valine is a slightly better inhibitor of KLK5 than KLK7.
The compounds with an IC 50 lower than 50 µM were chosen for further studies to determine their mechanism of inhibition. The inhibition of KLK5/KLK7 was measured at three different inhibitor concentrations and LineweaverBurk plots were prepared. The inhibition constants (K i ) were obtained through the secondary plot of K m /V max vs.
[I]. Representative plots for the best two inhibitors, compounds 6 and 7, are shown in Figure 2 . All of the inhibitions followed a competitive mechanism, and the Lineweaver-Burk plot (Figure 2A and 2C) reveals a common intersection point on the y-axis (1/V max ) at different inhibitor concentrations, but with different slopes (K m /V max ) and x-intercepts (-1/K m ). The K i value was obtained from the replot of the slopes (K m /V max ) vs.
[I] (Figure 2B and 2D) . This plot generates a straight line, which intersects the [I] axis at a value equal to -K i . The measured K i values are in reasonable agreement with IC 50 values, with the compounds 6-9 being the best inhibitors of KLK5 showing a K i in the range of 0.3 -0.7 µM. Compounds 7-9 were all similarly potent inhibitors of KLK7 with K i values ranging from 1.3 to 1.9 µM. A similar rank order was also observed in the K i values for the amide derivatives with compounds 16 and 19 inhibiting both enzymes in the low micromolar range.
To investigate the binding mode of these new inhibitors, we performed molecular docking studies with compound 6 and 14 into the KLK5 binding site using the structure of KLK5 in complex with the inhibitor leupeptin (11) 
to rationalize the difference in the potency of these two compounds. We then applied molecular dynamics simulation combined with Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) as a more accurate method to investigate the protein-ligand interactions (13) . The binding mode of the complexes identified with Autodock was used as starting structures for 10ns of MD simulations using AMBER (14) (for details see Supporting Information).
During 10 ns of molecular dynamics simulations, the complex between compound 6 and KLK5 (Figure 3a) showed a stable binding mode, which does not substantially diverge from the one previously obtained by docking, being observed only fluctuations in the O-benzyl moieties ( Figure S1 ). The binding of compound 6 is further stabilized by three hydrogen bonds with the backbone of Gly193, Ser214, and Gly216 (Figure 3a and Figure S2 ). For compound 14, significant differences in its position and conformation were observed throughout the MD simulation. The ligand gradually left the starting conformation and moves away from the binding pocket losing its contact with the enzyme (Figure 3b) . As a consequence, the hydrogen bonds with Ser195 and Gly193 are lost ( Figure S2 ). According to MM-GBSA calculations, these structural changes are reflected in the free energy of binding between compound 14 and KLK5 (∆G GBSA = −30.1 kcal/mol), which is around 17 kcal/mol lower than that obtained in the simulation of compound 6 (∆G GBSA = −46.9 kcal/mol), which corroborates our experimental results.
Previously, we have identified compound 20 (named 9g in that publication) as a selective KLK7 inhibitor over KLK5 (13) . In order to rationalize the observed structure-activity relationship trend it would be helpful to compare the structure of compound 6 and 14 with that of compound 20. First, the comparison between compounds 14 and 20 shows that they are highly similar (Figure 4) . The only differences are the replacement of the 2-methylthiophene (red) and phenyl moieties (blue) in 20 by a benzyl and N-Cbz-Lproline moieties, respectively, in compound 14. As a result of these changes, the potency against KLK7 is abolished along with the worsening of the inhibitory effects against KLK5. In compound 6, the same substituents, as in 14, replace the 2-methylthiophene and phenyl moieties in 20. Moreover, two other additional changes are observed. First the stereochemistry of the carbon atoms C-2 and C-4 in the isomannide ring which is 2S and 4S, respectively, in compounds 14 and 20 is converted to 2R, and 4R, respectively, in compound 6. This fact explains, at first glance, the reduced potency of compound 14. The second difference between compounds 14 (and 20) and 6 is the bioisosteric substitution of NH by O (green in Figure 4 ) group converting an amide into an ester. The amide-to-ester substitution reduces the electronegativity of the carbonyl oxygen, which weakens its hydrogen bonding acceptor strength and eliminates a hydrogen bond donor (15, 16) . In theory these factors would contribute negatively to the affinity of the compound since the amide-to-ester substitution will reduce the number and the strength of potential hydrogen bonds the compound can make. Also there is a reduction in the rotational barrier of the ester bond (11 kcal/mol) compared with that of amide bond (20 kcal/mol), increasing the conformational flexibility of the molecule. Locking the compound in its binding conformation or increasing its flexibility are well known strategies used in drug design (17, 18) . For the compounds evaluated in the present work the higher conformational flexibility is crucial for the biological activity of compound 6. In fact, along with being more rigid than 6 because of the higher rotational barrier of the amide bond, analysis of the MD simulations for compound 14 showed the presence of a stable intramolecular hydrogen bond between the amide nitrogen N-9 and the carbonyl oxygen O-30 producing a Figure 4 . Chemical structures of compounds 6, 14 and 20. The common substructure shared by the KLK5/KLK7 inhibitors is colored in black. The substituents 2-methylthiophene (red) and phenyl (blue) in 20 are replaced by a benzyl (red) and N-Cbz-Lproline (blue) moieties, respectively, in compounds 6 and 14. The green oxygen highlights the amide-to-ester substitution between 6 and 14.
seven-member heterocyclic ring. This imposes an additional conformational constraint to 14 reducing its ability to fit in the KLK5 binding site with the correct conformation. In 6 the amide-to-ester substitution prevents the formation of this intramolecular hydrogen bond. Taken together, the stereochemistry of the isomannide ring and the lower conformational flexibility provide insight to explain the reduced potency of the amide derivative 14 against KLK5.
The binding of compounds 6 and 14 to KLK7 were also investigated. In the MD simulation followed by the MM/GBSA calculations, the predicted free energy of binding for compound 6 (∆G GBSA = -32.9 kcal/mol) was lower than that of 14 (∆G GBSA = -38.9 kcal/mol), which contradicts the experimental data. Looking back to the docking results we noticed that the 2 nd ranked pose had almost the same energy than the 1 st one, with the phenylalanine side chain still occupying the S1 pocket, but the isomannide and pyrrolidine rings are placed in an opposite orientation. After the MD simulation of this pose the ∆G GBSA calculated using the MM/GBSA method was -40.0 and -35.6 kcal/mol for the compound 6 and 14, respectively. The 2 nd ranked pose of 6 is the ligand binding pose most likely to be correct since it is approximately 7 kcal/mol more stable than the one best ranked. The complex between compound 6 and KLK7 (Figure S4 ) exhibited a stable binding mode, stabilized by two hydrogen bonds with Asn192 Gly193 amino acids ( Figure  S5) . A similar binding pose was observed for the KLK7-14 complex, and the interaction is stabilized by two hydrogen bonds with Asn192 and Ser195 ( Figure S5 ).
KLK5 is a trypsin-like serino protease with a negatively charged Asp189 and the polar Ser190 at the bottom of the S1 pocket. On the other hand, KLK7 is a chymotrypsin-like protease, with a polar Asn189 and a hydrophobic Ala190 at the S1 pocket. Also, the side chains of Tyr218 and Gln192, which frames the entrance to the KLK5 S1 pocket, are replaced by Phe218 and Asn192 in KLK7. These differences make the S1 pocket in KLK7 more open and hydrophobic. These observations provide support for the design of more potent and selective inhibitors for KLK5 and KLK7. Although the phenylalanine side chain of compound 6 binds inside the S1 pocket in both enzymes, this moiety does not fully occupy the pocket or make direct contacts with the amino acids 189 and 190. So, for example, replacing the phenyl ring in the phenylalanine by the benzamidine group, that mimics the arginine side chain, would extend further the inhibitor into the S1 pocket where additional interactions could be formed with the Asp189 and Ser190.
In conclusion, we reported a new class of small isomannide-based peptidomimetic compounds that inhibit the activity of KLK5 and KLK7. Enzyme kinetics studies and the determination of the mechanism of inhibition confirmed that all of the compounds are competitive inhibitors of KLK5 and KLK7. Compared to our previous hit, the introduction of new structural moieties and changes in the stereochemistry of the isomannide ring, as well as an amide-to-ester substitution resulted in a new series of isomannide-based ester derivatives with K i values in the sub-micromolar range and rank among the best inhibitors of KLK5 reported so far. Docking and molecular dynamics studies allowed us to rationalize the difference in activity between the new series of compounds. Thus, the novel KLK5 inhibitors reported here represent potential leads for future optimization studies.
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